Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
23 08 2022
23 08 2022
Historique:
received:
20
08
2021
accepted:
16
03
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
25
8
2022
Statut:
ppublish
Résumé
We assessed whether novelty-related fMRI activity in medial temporal lobe regions and the precuneus follows an inverted U-shaped pattern across the clinical spectrum of increased Alzheimer disease (AD) risk as previously suggested. Specifically, we tested for potentially increased activity in individuals with a higher AD risk due to subjective cognitive decline (SCD) or mild cognitive impairment (MCI). We further tested whether activity differences related to diagnostic groups were accounted for by CSF markers of AD or brain atrophy. We studied 499 participants aged 60-88 years from the German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia Study (DELCODE) who underwent task-fMRI. Participants included 163 cognitively normal (healthy control, HC) individuals, 222 SCD, 82 MCI, and 32 patients with clinical diagnosis of mild AD. CSF levels of β-amyloid 42/40 ratio and phosphorylated-tau181 were available from 232 participants. We used region-based analyses to assess novelty-related activity (novel > highly familiar scenes) in entorhinal cortex, hippocampus, and precuneus as well as whole-brain voxel-wise analyses. First, general linear models tested differences in fMRI activity between participant groups. Complementary regression models tested quadratic relationships between memory impairment and activity. Second, relationships of activity with AD CSF biomarkers and brain volume were analyzed. Analyses were controlled for age, sex, study site, and education. In the precuneus, we observed an inverted U-shaped pattern of novelty-related activity across groups, with higher activity in SCD and MCI compared with HC, but not in patients with AD who showed relatively lower activity than MCI. This nonlinear pattern was confirmed by a quadratic relationship between memory impairment and precuneus activity. Precuneus activity was not related to AD biomarkers or brain volume. In contrast to the precuneus, hippocampal activity was reduced in AD dementia compared with all other groups and related to AD biomarkers. Novelty-related activity in the precuneus follows a nonlinear pattern across the clinical spectrum of increased AD risk. Although the underlying mechanism remains unclear, increased precuneus activity might represent an early signature of memory impairment. Our results highlight the nonlinearity of activity alterations that should be considered in clinical trials using functional outcome measures or targeting hyperactivity.
Sections du résumé
BACKGROUND AND OBJECTIVES
We assessed whether novelty-related fMRI activity in medial temporal lobe regions and the precuneus follows an inverted U-shaped pattern across the clinical spectrum of increased Alzheimer disease (AD) risk as previously suggested. Specifically, we tested for potentially increased activity in individuals with a higher AD risk due to subjective cognitive decline (SCD) or mild cognitive impairment (MCI). We further tested whether activity differences related to diagnostic groups were accounted for by CSF markers of AD or brain atrophy.
METHODS
We studied 499 participants aged 60-88 years from the German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia Study (DELCODE) who underwent task-fMRI. Participants included 163 cognitively normal (healthy control, HC) individuals, 222 SCD, 82 MCI, and 32 patients with clinical diagnosis of mild AD. CSF levels of β-amyloid 42/40 ratio and phosphorylated-tau181 were available from 232 participants. We used region-based analyses to assess novelty-related activity (novel > highly familiar scenes) in entorhinal cortex, hippocampus, and precuneus as well as whole-brain voxel-wise analyses. First, general linear models tested differences in fMRI activity between participant groups. Complementary regression models tested quadratic relationships between memory impairment and activity. Second, relationships of activity with AD CSF biomarkers and brain volume were analyzed. Analyses were controlled for age, sex, study site, and education.
RESULTS
In the precuneus, we observed an inverted U-shaped pattern of novelty-related activity across groups, with higher activity in SCD and MCI compared with HC, but not in patients with AD who showed relatively lower activity than MCI. This nonlinear pattern was confirmed by a quadratic relationship between memory impairment and precuneus activity. Precuneus activity was not related to AD biomarkers or brain volume. In contrast to the precuneus, hippocampal activity was reduced in AD dementia compared with all other groups and related to AD biomarkers.
DISCUSSION
Novelty-related activity in the precuneus follows a nonlinear pattern across the clinical spectrum of increased AD risk. Although the underlying mechanism remains unclear, increased precuneus activity might represent an early signature of memory impairment. Our results highlight the nonlinearity of activity alterations that should be considered in clinical trials using functional outcome measures or targeting hyperactivity.
Identifiants
pubmed: 35995589
pii: WNL.0000000000200667
doi: 10.1212/WNL.0000000000200667
pmc: PMC9484732
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e775-e788Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Nat Commun. 2017 Oct 31;8(1):1214
pubmed: 29089479
Behav Neurol. 2009;21(1):77-91
pubmed: 19847047
Acta Psychiatr Scand. 2014 Dec;130(6):439-51
pubmed: 25219393
Neurosci Biobehav Rev. 2014 Sep;45:246-57
pubmed: 24973756
J Neurosci. 2021 Apr 28;41(17):3917-3931
pubmed: 33731446
Nat Neurosci. 2014 Oct;17(10):1316-8
pubmed: 25217827
Ann Neurol. 2017 Apr;81(4):583-596
pubmed: 28253546
Neuron. 2012 May 10;74(3):467-74
pubmed: 22578498
J Alzheimers Dis. 2021;79(2):493-509
pubmed: 33337359
Neurology. 2012 Sep 25;79(13):1332-9
pubmed: 22914828
Hippocampus. 2011 Aug;21(8):803-14
pubmed: 20665594
Cereb Cortex. 2012 Aug;22(8):1813-23
pubmed: 21945849
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
J Alzheimers Dis. 2018;63(4):1523-1535
pubmed: 29782316
Neuroimage. 2011 Apr 1;55(3):954-67
pubmed: 21216294
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Am J Geriatr Psychiatry. 2008 Apr;16(4):283-92
pubmed: 18378553
J Alzheimers Dis. 2012;29(1):109-23
pubmed: 22214785
Alzheimers Dement (Amst). 2021 Jan 20;12(1):e12139
pubmed: 33521234
Brain. 2016 Feb;139(Pt 2):547-62
pubmed: 26586695
J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):630-5
pubmed: 17846109
J Neurosci. 2014 Apr 9;34(15):5200-10
pubmed: 24719099
J Neurosci. 2019 Jan 16;39(3):548-556
pubmed: 30482786
Brain. 2019 Aug 1;142(8):2492-2509
pubmed: 31199481
Neurobiol Aging. 2012 Jul;33(7):1237-52
pubmed: 21334099
Commun Biol. 2019 Oct 10;2:370
pubmed: 31633061
J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):812-8
pubmed: 17287238
Eur Psychiatry. 2011 Oct;26(7):457-62
pubmed: 20932721
Nat Neurosci. 2010 Jul;13(7):812-8
pubmed: 20581818
J Neurosci. 2014 Jan 15;34(3):932-40
pubmed: 24431451
J Neurosci. 2017 Apr 19;37(16):4323-4331
pubmed: 28314821
CNS Neurosci Ther. 2019 Jan;25(1):5-13
pubmed: 30101571
Cereb Cortex. 2019 May 1;29(5):1997-2009
pubmed: 29912295
Brain. 2022 May 24;145(4):1473-1485
pubmed: 35352105
J Neurosci. 2006 Oct 4;26(40):10222-31
pubmed: 17021177
Neuroimage. 2018 Feb 1;166:285-292
pubmed: 29108941
Nat Neurosci. 2016 Aug;19(8):1085-92
pubmed: 27322420
J Neurosci. 2011 Nov 30;31(48):17680-8
pubmed: 22131428
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
Neurology. 2003 Aug 26;61(4):500-6
pubmed: 12939424
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Neurology. 2020 Sep 1;95(9):e1134-e1143
pubmed: 32636322
JAMA. 2014 Dec 17;312(23):2551-61
pubmed: 25514304
Alzheimers Dement (Amst). 2018 Nov 02;10:782-790
pubmed: 30555890
Alzheimers Res Ther. 2020 Oct 19;12(1):133
pubmed: 33076977
Arch Gen Psychiatry. 2011 Aug;68(8):845-52
pubmed: 21810648
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Alzheimers Dement (Amst). 2015 Dec 11;1(4):487-504
pubmed: 27239527
Neuron. 2009 Jul 30;63(2):178-88
pubmed: 19640477
Alzheimers Res Ther. 2018 Feb 07;10(1):15
pubmed: 29415768